Shlomo Melmed

List of Publications by Citations

234 papers	19,162 citations	73 h-index	135 g-index
251 ext. papers	22,271 ext. citations	9 avg, IF	7.32 L-index

#	Paper	IF	Citations
234	Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 273-88	5.6	967
233	Acromegaly: an endocrine society clinical practice guideline. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 3933-51	5.6	923
232	Medical progress: Acromegaly. *New England Journal of Medicine*, **2006**, 355, 2558-73	59.2	850
231	Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 2990-3011	5.6	830
230	Criteria for cure of acromegaly: a consensus statement. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 526-9	5.6	727
229	Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. *Lancet, The*, **2001**, 358, 1754-9	40	499
228	Acromegaly. *New England Journal of Medicine*, **1990**, 322, 966-77	59.2	481
227	Isolation and characterization of a pituitary tumor-transforming gene (PTTG). *Molecular Endocrinology*, **1997**, 11, 433-41		458
226	Clonal origin of pituitary adenomas. *Journal of Clinical Endocrinology and Metabolism*, **1990**, 71, 1427-33	5.6	458
225	Acromegaly pathogenesis and treatment. *Journal of Clinical Investigation*, **2009**, 119, 3189-202	15.9	424
224	Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 3888-3921	5.6	404
223	Pathogenesis of pituitary tumors. *Nature Reviews Endocrinology*, **2011**, 7, 257-66	15.2	336
222	Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 761-7	5.6	314
221	Mechanisms for pituitary tumorigenesis: the plastic pituitary. *Journal of Clinical Investigation*, **2003**, 112, 1603-18	15.9	291
220	Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. *Nature Medicine*, **1999**, 5, 1317-21	50.5	279
219	Expert consensus document: A consensus on the medical treatment of acromegaly. *Nature Reviews Endocrinology*, **2014**, 10, 243-8	15.2	255
218	Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). *Molecular Endocrinology*, **1999**, 13, 156-66		241

217	A Consensus Statement on acromegaly therapeutic outcomes. *Nature Reviews Endocrinology*, **2018**, 14, 552-561	15.2	216
216	Expression of pituitary-tumour transforming gene in colorectal tumours. *Lancet, The*, **2000**, 355, 716-9	40	206
215	Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. *Endocrine Reviews*, **2007**, 28, 165-86	27.2	202
214	Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. *Nature Medicine*, **2002**, 8, 1281-7	50.5	202
213	Octreotide as primary therapy for acromegaly. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 3034-40	5.6	181
212	EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. *Journal of Clinical Investigation*, **2011**, 121, 4712-21	15.9	177
211	Pituitary cytokine and growth factor expression and action. *Endocrine Reviews*, **1997**, 18, 206-28	27.2	170
210	A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 4405-10	5.6	168
209	Acromegaly. *Endocrinology and Metabolism Clinics of North America*, **2008**, 37, 101-22, viii	5.5	163
208	Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. *Molecular Endocrinology*, **2001**, 15, 1870-9		161
207	Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. *Pituitary*, **2017**, 20, 489-498	4.3	157
206	Pituitary-Tumor Endocrinopathies. *New England Journal of Medicine*, **2020**, 382, 937-950	59.2	155
205	A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 2957-68	5.6	152
204	Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 1633-41	5.6	150
203	Pituitary somatostatin receptor signaling. *Trends in Endocrinology and Metabolism*, **2010**, 21, 123-33	8.8	149
202	Pathophysiology of acromegaly. *Endocrine Reviews*, **1983**, 4, 271-90	27.2	130
201	Acromegaly. *Nature Reviews Disease Primers*, **2019**, 5, 20	51.1	128
200	Meta-analysis on the effects of octreotide on tumor mass in acromegaly. *PLoS ONE*, **2012**, 7, e36411	3.7	128

199	Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. *New England Journal of Medicine*, **1985**, 312, 9-17	59.2	121
198	The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 523-7	5.6	120
197	p21(Cip1) restrains pituitary tumor growth. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 17498-503	11.5	120
196	Functional role of estrogen in pituitary tumor pathogenesis. *Journal of Clinical Investigation*, **2002**, 109, 277-283	15.9	117
195	PPAR-□eceptor ligands: novel therapy for pituitary adenomas. *Journal of Clinical Investigation*, **2003**, 111, 1381-1388	15.9	116
194	Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis. *Molecular Endocrinology*, **2005**, 19, 2371-9		115
193	Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 1388-91	5.6	115
192	Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 1699-708	5.6	114
191	Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. *Journal of Clinical Investigation*, **2004**, 114, 349-56	15.9	111
190	Human pituitary tumor-transforming gene induces angiogenesis. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 867-74	5.6	108
189	Genetic basis of endocrine disease: pituitary tumor pathogenesis. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 1675-81	5.6	107
188	Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. *Endocrinology*, **2003**, 144, 4991-8	4.8	107
187	Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 1825-33	5.6	106
186	Body mass index determines evoked growth hormone (GH) responsiveness in normal healthy male subjects: diagnostic caveat for adult GH deficiency. *Journal of Clinical Endocrinology and Metabolism* , **2004**, 89, 3397-401	5.6	104
185	Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. *Pituitary*, **2010**, 13, 18-28	4.3	102
184	International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. *Pharmacological Reviews*, **2018**, 70, 763-835	22.5	101
183	Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 8414-9	11.5	99
182	Molecular targets in pituitary tumours. *Nature Reviews Cancer*, **2004**, 4, 285-95	31.3	99

181	Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. *Molecular Endocrinology*, **2005**, 19, 1383-91		95
180	Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. *Cancer Research*, **2007**, 67, 10564-72	10.1	91
179	Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. *Molecular Endocrinology*, **2000**, 14, 1137-46		88
178	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	88
177	Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. *Journal of Biological Chemistry*, **2000**, 275, 36502-5	5.4	84
176	Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor. *Journal of Clinical Investigation*, **1999**, 104, 1277-85	15.9	82
175	Pregnancy in acromegaly: successful therapeutic outcome. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 727-31	5.6	81
174	Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing. *Journal of Clinical Investigation*, **2000**, 106, 1417-25	15.9	80
173	MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study. *Journal of the Endocrine Society*, **2020**, 4,	0.4	78
172	MON-LB57 Impact of Imputation Method and Response Cutoffs on Results From the Phase 3 OPTIMAL Study of Oral Octreotide Capsules in Adult Patients With Acromegaly. *Journal of the Endocrine Society*, **2020**, 4,	0.4	78
171	OR16-06 Age-Associated Local GH Promotes Colon Neoplasia. *Journal of the Endocrine Society*, **2020**, 4,	0.4	78
170	MON-LB55 Biochemical Control of Most Patients Reverting to Injectable Long-Acting Somatostatin Receptor Ligands Is Achieved After One Dose: Results From the Phase 3, Randomized, Double Blind, Placebo-Controlled Optimal Study. *Journal of the Endocrine Society*, **2020**, 4,	0.4	78
169	MON-314 Analysis of Adverse Events in Adult Patients with Acromegaly Receiving Oral Octreotide Capsules: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study. *Journal of the Endocrine Society*, **2020**, 4,	0.4	78
168	MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study. *Journal of the Endocrine Society*, **2020**, 4,	0.4	78
167	Pituitary Somatotroph Adenoma Cell-Derived Exosomes: Characterization of Novel Non-Hormonal Functions. *Journal of the Endocrine Society*, **2021**, 5, A652-A653	0.4	78
166	Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands: Results From the MPOWERED Trial. *Journal of the Endocrine Society*, **2021**, 5, A522-A523	0.4	78
165	GH Is a Component of SASP in Aging Tissue. *Journal of the Endocrine Society*, **2021**, 5, A539-A540	0.4	78
164	Safety Results From MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults With Acromegaly. *Journal of the Endocrine Society*, **2021**, 5, A527-A528	0.4	78

163	Somatostatin agonists for treatment of acromegaly. *Molecular and Cellular Endocrinology*, **2008**, 286, 192-8	4.4	76
162	Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 3428-32	11.5	75
161	Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 5414-21	5.6	73
160	Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 2958-61	5.6	73
159	Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 4239-45	5.6	72
158	Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 4759-67	5.6	71
157	The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 3027-32	5.6	71
156	Functional role of estrogen in pituitary tumor pathogenesis. *Journal of Clinical Investigation*, **2002**, 109, 277-83	15.9	71
155	Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 249-56	5.6	68
154	Multidisciplinary management of acromegaly: A consensus. *Reviews in Endocrine and Metabolic Disorders*, **2020**, 21, 667-678	10.5	67
153	Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 980-8	5.6	66
152	Interleukin-11 stimulates proopiomelanocortin gene expression and adrenocorticotropin secretion in corticotroph cells: evidence for a redundant cytokine network in the hypothalamo-pituitary-adrenal axis. *Endocrinology*, **1999**, 140, 1559-66	4.8	64
151	A structural and functional acromegaly classification. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 122-31	5.6	63
150	Transforming DNA sequences present in human prolactin-secreting pituitary tumors. *Molecular Endocrinology*, **1991**, 5, 1687-95		63
149	Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. *Hormones and Cancer*, **2010**, 1, 80-92	5	62
148	Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. *Cancer Research*, **2008**, 68, 6377-86	10.1	59
147	Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. *Endocrinology*, **2006**, 147, 4781-91	4.8	59
146	The central role of SOCS-3 in integrating the neuro-immunoendocrine interface. *Journal of Clinical Investigation*, **2001**, 108, 1735-1740	15.9	58

145	A common pro-opiomelanocortin-binding element mediates leukemia inhibitory factor and corticotropin-releasing hormone transcriptional synergy. *Journal of Biological Chemistry*, **1997**, 272, 10551-7	5.4	55
144	PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. *Journal of Clinical Investigation*, **2003**, 111, 1381-8	15.9	55
143	Subclinical hyperfunctioning pituitary adenomas: the silent tumors. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2012**, 26, 447-60	6.5	54
142	Oncogene activation in pituitary tumors. *Brain Pathology*, **2001**, 11, 328-41	6	54
141	Pituitary tumors. *Endocrinology and Metabolism Clinics of North America*, **2015**, 44, 1-9	5.5	53
140	HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. *Molecular Endocrinology*, **2011**, 25, 92-103		52
139	Growth hormone is permissive for neoplastic colon growth. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E3250-9	11.5	52
138	Expression and function of ErbB receptors and ligands in the pituitary. *Endocrine-Related Cancer*, **2011**, 18, R197-211	5.7	51
137	Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 963-8	5.6	51
136	Skin manifestations in acromegaly. *Clinics in Dermatology*, **2006**, 24, 256-9	3	50
135	A Pituitary Society update to acromegaly management guidelines. *Pituitary*, **2021**, 24, 1-13	4.3	50
134	Consensus on diagnosis and management of Cushing's disease: a guideline update. *Lancet Diabetes and Endocrinology,the*, **2021**, 9, 847-875	18.1	48
133	A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. *Journal of Clinical Investigation*, **2012**, 122, 3295-306	15.9	47
132	Pathogenesis and Diagnosis of Growth Hormone Deficiency in Adults. *New England Journal of Medicine*, **2019**, 380, 2551-2562	59.2	46
131	New therapeutic agents for acromegaly. *Nature Reviews Endocrinology*, **2016**, 12, 90-8	15.2	46
130	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. *British Journal of Pharmacology*, **2021**, 178 Suppl 1, S27-S156	8.6	46
129	Growth hormone is a cellular senescence target in pituitary and nonpituitary cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E3331-9	11.5	45
128	Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 392-9	5.6	45

127	Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 2557-64	5.6	44
126	Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. *PLoS ONE*, **2011**, 6, e17924	3.7	42
125	Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. *Journal of Biological Chemistry*, **2005**, 280, 24011-21	5.4	42
124	A tale of pituitary adenomas: to NET or not to NET : Pituitary Society position statement. *Pituitary*, **2019**, 22, 569-573	4.3	41
123	Pituitary tumor transforming gene (PTTG) transforming and transactivation activity. *Journal of Biological Chemistry*, **2000**, 275, 7459-61	5.4	41
122	An intronless homolog of human proto-oncogene hPTTG is expressed in pituitary tumors: evidence for hPTTG family. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 1149-52	5.6	41
121	Medical management of acromegaly due to ectopic production of growth hormone-releasing hormone by a carcinoid tumor. *Journal of Clinical Endocrinology and Metabolism*, **1988**, 67, 395-9	5.6	40
120	Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors. *Neurosurgery*, **2017**, 81, 357-366	3.2	39
119	STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion. *Journal of Clinical Investigation*, **2015**, 125, 1692-702	15.9	39
118	Idiopathic adult growth hormone deficiency. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 2187-97	5.6	39
117	SAGIT : clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot study. *Pituitary*, **2016**, 19, 39-49	4.3	37
116	Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: marker of tumour invasiveness. *Clinical Endocrinology*, **1998**, 48, 23-9	3.4	37
115	Zebrafish usp39 mutation leads to rb1 mRNA splicing defect and pituitary lineage expansion. *PLoS Genetics*, **2011**, 7, e1001271	6	36
114	Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation. *Molecular Endocrinology*, **2007**, 21, 2565-78		36
113	Pituitary senescence: the evolving role of Pttg. *Molecular and Cellular Endocrinology*, **2010**, 326, 55-9	4.4	34
112	The cell adhesion molecules N-cadherin and neural cell adhesion molecule regulate human growth hormone: a novel mechanism for regulating pituitary hormone secretion. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 3724-30	5.6	33
111	E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors. *Molecular Endocrinology*, **2009**, 23, 2000-12		32
110	Heregulin regulates prolactinoma gene expression. *Cancer Research*, **2009**, 69, 4209-16	10.1	31

109	Pituitary Medicine From Discovery to Patient-Focused Outcomes. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 769-77	5.6	30
108	Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression. *Molecular Endocrinology*, **2003**, 17, 600-9		30
107	ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice. *Endocrinology*, **2015**, 156, 71-9	4.8	29
106	Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	29
105	EGFR Induces E2F1-Mediated Corticotroph Tumorigenesis. *Journal of the Endocrine Society*, **2017**, 1, 127-143	3.4	27
104	Constitutive somatostatin receptor activity determines tonic pituitary cell response. *Molecular Endocrinology*, **2009**, 23, 337-48		27
103	Recurrent acromegaly resulting from ectopic growth hormone gene expression by a metastatic pancreatic tumor. *Cancer*, **1993**, 71, 66-70	6.4	27
102	Treatment of acromegaly: future. *Endocrine*, **2005**, 28, 123-8		26
101	Leukemia inhibitory factor regulates proopiomelanocortin transcription. *Annals of the New York Academy of Sciences*, **1998**, 840, 162-73	6.5	25
100	Structure of the thyrotrophin-releasing hormone receptor in human pituitary adenomas. *Clinical Endocrinology*, **1996**, 44, 341-7	3.4	25
99	Genomic characterization of human and rat prolactinomas. *Endocrinology*, **2012**, 153, 3679-91	4.8	24
98	In vivo regulation of hepatic insulin-like growth factor-1 messenger ribonucleic acids with thyroid hormone. *Endocrinologia Japonica*, **1990**, 37, 205-11		24
97	Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growth. *Molecular Endocrinology*, **2012**, 26, 2092-103		23
96	Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro. *Molecular and Cellular Endocrinology*, **2012**, 362, 104-9	4.4	23
95	Pathogenesis of pituitary tumors. *Progress in Brain Research*, **2010**, 182, 207-27	2.9	22
94	Excess growth hormone suppresses DNA damage repair in epithelial cells. *JCI Insight*, **2019**, 4,	9.9	21
93	Pathogenesis of pituitary tumors. *Endocrinology and Metabolism Clinics of North America*, **1999**, 28, 1-12, v	5.5	21
92	Pituitary tumor-transforming gene 1 regulates the patterning of retinal mosaics. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 9295-300	11.5	20

91	Pituitary adenoma growth: A model for cellular senescence and cytokine action. *Cell Cycle*, **2009**, 8, 677-682	4.7	20
90	Characterization of the murine pituitary tumor transforming gene (PTTG) and its promoter. *Endocrinology*, **2000**, 141, 763-71	4.8	20
89	Pituitary Physiology and Diagnostic Evaluation **2011**, 175-228		20
88	Localization of somatostatin receptors in secretion vesicles in anterior pituitary cells and pancreatic islets. *Journal of Receptors and Signal Transduction*, **1985**, 5, 83-103		19
87	Sca1+ murine pituitary adenoma cells show tumor-growth advantage. *Endocrine-Related Cancer*, **2014**, 21, 203-16	5.7	18
86	A novel molecular marker of pituitary tumor transforming gene involves in a rat liver regeneration. *Journal of Surgical Research*, **2005**, 129, 142-6	2.5	18
85	PTTG1 attenuates drug-induced cellular senescence. *PLoS ONE*, **2011**, 6, e23754	3.7	18
84	Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas. *Pituitary*, **2017**, 20, 93-99	4.3	17
83	Acromegaly: assessing the disorder and navigating therapeutic options for treatment. *Endocrine Practice*, **2014**, 20 Suppl 1, 7-17; quiz 18-20	3.2	17
82	Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 3409-16	5.6	17
81	DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas. *Journal of Clinical Investigation*, **2020**, 130, 5738-5755	15.9	17
80	Pituitary Neoplasia. *Endocrinology and Metabolism Clinics of North America*, **1994**, 23, 81-92	5.5	17
79	E2F1-mediated human POMC expression in ectopic Cushing's syndrome. *Endocrine-Related Cancer*, **2016**, 23, 857-870	5.7	16
78	CEBPD suppresses prolactin expression and prolactinoma cell proliferation. *Molecular Endocrinology*, **2011**, 25, 1880-91		16
77	In vivo time-lapse imaging delineates the zebrafish pituitary proopiomelanocortin lineage boundary regulated by FGF3 signal. *Developmental Biology*, **2008**, 319, 192-200	3.1	16
76	Growth factors and cytokines in paragangliomas and pheochromocytomas, with special reference to sustentacular cells. *Endocrine Pathology*, **2002**, 13, 197-206	4.2	16
75	EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e917-e925	5.6	16
74	Stimulatory effect of leukemia inhibitory factor on ACTH secretion of dispersed rat pituitary cells. *Endocrine Research*, **1999**, 25, 11-9	1.9	15

73	Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells. *Endocrinology*, **2017**, 158, 2255-2268	4.8	14
72	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. *Journal of the Endocrine Society*, **2021**, 5, bvaa205	0.4	14
71	Growth Hormone Induces Colon DNA Damage Independent of IGF-1. *Endocrinology*, **2019**, 160, 1439-1447	4.8	13
70	Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT validation study. *Pituitary*, **2019**, 22, 476-487	4.3	13
69	Pituitary Masses and Tumors **2016**, 232-299		13
68	Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. *IDrugs: the Investigational Drugs Journal*, **2007**, 10, 885-95		13
67	Altered Pituitary Gland Structure and Function in Posttraumatic Stress Disorder. *Journal of the Endocrine Society*, **2017**, 1, 577-587	0.4	12
66	Constitutive somatostatin receptor subtype-3 signaling suppresses growth hormone synthesis. *Molecular Endocrinology*, **2014**, 28, 554-64		12
65	Fibroblast growth factor-2 autofeedback regulation in pituitary folliculostellate TtT/GF cells. *Endocrinology*, **2009**, 150, 3252-8	4.8	12
64	The tale in evolution: clarity, consistency and consultation, not contradiction and confusion. *Pituitary*, **2020**, 23, 476-477	4.3	12
63	Discordant proliferation and differentiation in pituitary tumor-transforming gene-null bone marrow stem cells. *American Journal of Physiology - Cell Physiology*, **2007**, 293, C1082-92	5.4	11
62	Expression of leukemia inhibitory factor in human pituitary adenomas: a morphologic and immunocytochemical study. *Pituitary*, **2000**, 2, 245-51	4.3	11
61	Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. *Nature Clinical Practice Endocrinology and Metabolism*, **2006**, 2, 408-12; quiz following 412		10
60	The IGF-I receptor sub-membrane domain is intact in GH-secreting pituitary tumours. *Clinical Endocrinology*, **1995**, 42, 169-72	3.4	10
59	Acromegaly Consensus: The Next Steps. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 1913-1914	5.6	10
58	Growth hormone in the tumor microenvironment. *Archives of Endocrinology and Metabolism*, **2019**, 63, 568-575	2.2	10
57	Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	10
56	Clinical factors associated with biochemical adrenal-cortisol insufficiency in hospitalized patients. *American Journal of Medicine*, **2014**, 127, 754-762	2.4	9

55	Constitutive activity of somatostatin receptor subtypes. *Methods in Enzymology*, **2010**, 484, 149-64	1.7	9
54	Prospective Evaluation of Incidental Pituitary Imaging Findings in the Sella Turcica. *Journal of the Endocrine Society*, **2021**, 5, bvaa186	0.4	9
53	The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome. *Pituitary*, **2010**, 13, 266-86	4.3	7
52	Molecular pathogenesis of acromegaly. *Pituitary*, **1999**, 2, 43-50	4.3	7
51	Estradiol partially recapitulates murine pituitary cell cycle response to pregnancy. *Endocrinology*, **2012**, 153, 5011-22	4.8	6
50	Leukemia inhibitory factor (LIF) modulates pro-opiomelanocortin (POMC) gene regulation in stably transfected AtT-20 cells overexpressing LIF. *Endocrine*, **1997**, 7, 325-30		6
49	Establishment of functional human pituitary tumor cell cultures. *In Vitro*, **1982**, 18, 35-42		6
48	Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.. *Lancet Diabetes and Endocrinology,the*, **2021**,	18.1	6
47	Growth Hormone **2017**, 85-127		5
46	Aryl hydrocarbon receptor interacting protein and pituitary tumorigenesis: another interesting protein. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 1617-9	5.6	5
45	Molecular pathogenesis of pituitary disorders. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2002**, 9, 61-78		5
44	SUN-442 EGFR/ErbB2 Targeted Therapy for Aggressive Prolactinomas. *Journal of the Endocrine Society*, **2019**, 3,	0.4	5
43	Two Distinctive POMC Promoters Modify Gene Expression in Cushing Disease. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e3346-e3363	5.6	5
42	Peptide Hormone Regulation of DNA Damage Responses. *Endocrine Reviews*, **2020**, 41,	27.2	5
41	Expression of leukemia inhibitory factor in craniopharyngioma. *Endocrine Pathology*, **1999**, 10, 103-8	4.2	4
40	Oncogenes and Tumor Suppressor Genes in Pituitary Tumorigenesis. *Frontiers of Hormone Research*, **1996**, 20, 122-136	3.5	4
39	Longitudinal assessment of response to treatment with oral octreotide capsules in patients with acromegaly: post-hoc analysis of a phase 3 trial. *Endocrine Abstracts*,		4
38	Safety of growth hormone replacement in survivors of cancer and intra-cranial and pituitary tumours - A consensus statement.. *European Journal of Endocrinology*, **2022**,	6.5	4

37	Growth Hormone **2011**, 83-117		3
36	MON-459 ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, Attenuates GH Hypersecretion in Human GH-Secreting, Pituitary Adenoma-Derived Cells. *Journal of the Endocrine Society*, **2019**, 3,	0.4	3
35	Pituitary Function and Neoplasia **1998**, 443-449		3
34	Pituitary Masses and Tumors **2011**, 229-290		3
33	Proton Sensitivity of Corticotropin-Releasing Hormone Receptor 1 Signaling to Proopiomelanocortin in Male Mice. *Endocrinology*, **2019**, 160, 276-291	4.8	3
32	Clinical Biology of the Pituitary Adenoma.. *Endocrine Reviews*, **2022**,	27.2	3
31	Endocrinology research-reflecting on the past decade and looking to the next. *Nature Reviews Endocrinology*, **2015**, 11, 672-80	15.2	2
30	Orchestrates Gene Regulatory Variation in Mouse Ventral Midbrain During Aging. *Frontiers in Genetics*, **2020**, 11, 566734	4.5	2
29	The Pituitary **2006**,		2
28	2004 World Health Organization classification of pituitary tumors: what is new?. *Acta Neuropathologica*, **2006**, 111, 78-9	14.3	2
27	Growth Hormone Excess and Cancer. *Rejuvenation Research*, **2001**, 4, 373-381		2
26	Fertility and fragrance: another cause of Kallmann syndrome. *Journal of Clinical Investigation*, **2015**, 125, 2275-8	15.9	2
25	Results from the phase 3, randomized, double-blind, placebo-controlled OPTIMAL study of oral octreotide capsules in adult patients with acromegaly. *Endocrine Abstracts*,		2
24	Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States.. *Pituitary*, **2022**, 1	4.3	2
23	The Pharmacological Burden of Comorbidities in Acromegaly. *Journal of the Endocrine Society*, **2021** , 5, A649-A650	0.4	2
22	THYMIC CARCINOID WITH ADRENOCORTICOTROPIC HORMONE-PRODUCING ECTOPIC CUSHING SYNDROME AND EMPTY SELLA. *AACE Clinical Case Reports*, **2018**, 4, e375-e378	0.7	2
21	Plurihormonal Adenomas. *Contemporary Endocrinology*, **2019**, 205-217	0.3	1
20	OR23-07 Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study of Oral Octreotide Capsules in Adult Patients with Acromegaly. *Journal of the Endocrine Society*, **2020**, 4,	0.4	1

19	Pituitary Adenomas **2012**, 739-760		1
18	Pituitary hormone receptors and tumorigenesis. *Nature Reviews Cancer*, **2007**, 7, 722-722	31.3	1
17	Cyclin-dependent kinase inhibitor gene polymorphisms in pituitary gigantism. *Endocrine*, **2006**, 29, 119-20		1
16	MON-323 IGF-I Variability and Its Association with Demographic and Clinical Characteristics in Patients with Acromegaly Treated with Injectable Somatostatin Receptor Ligands (SRLS); Results from an International Prospective Phase III Study. *Journal of the Endocrine Society*, **2020**, 4,	0.4	1
15	A Consensus Statement on acromegaly therapeutic outcomes		1
14	Insulin-like Growth Factor 1 and Prolactin Levels in Chimpanzees (Pan troglodytes) Across the Lifespan. *Journal of the Endocrine Society*, **2021**, 5, bvab063	0.4	1
13	Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy. *Journal of the Endocrine Society*, **2021**, 5, A518-A519	0.4	1
12	International Multicenter Validation Study of the SAGIT Instrument in Acromegaly. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 3555-3568	5.6	1
11	Pituitary somatotroph adenoma-derived exosomes: characterization of nonhormonal actions. *Journal of Clinical Endocrinology and Metabolism*, **2021**,	5.6	1
10	Pituitary stem cells. *Vitamins and Hormones*, **2021**, 116, 1-19	2.5	1
9	Local non-pituitary growth hormone is induced with aging and facilitates epithelial damage.. *Cell Reports*, **2021**, 37, 110068	10.6	0
8	GH and Senescence: A New Understanding of Adult GH Action.. *Journal of the Endocrine Society*, **2022**, 6, bvab177	0.4	0
7	Clinically Nonfunctioning Sellar Masses **2016**, 256-265.e3		
6	Melvin M. Grumbach 1925-2016. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 4845-4847	11.5	
5	Genetic Factors in Cushing Disease Pathogenesis **2014**, 365-371		
4	gp130-Related Cytokines **2000**, 115-132		
3	Pathogenesis of Corticotropic Tumors **2010**, 31-40		
2	Clinically Nonfunctioning Sellar Masses **2010**, 312-323		

1 Molecular Biology of Cushing Disease. *Growth Hormone*, **2011**, 19-32